Major depressive disorder and substance use disorder rarely travel alone. In people with depression, an estimated 25 percent also live with a substance use disorder, and the true figure is likely higher because overlapping symptoms make the second condition easy to miss. Alcohol is the substance most commonly misused in the context of depression, followed by cannabis and other illicit drugs. A new perspective article published in Frontiers in Psychiatry on 28 October 2026 argues that this combination is so common, and so poorly served by existing guidelines, that clinicians need a deliberately individualized, multidisciplinary playbook rather than a one-size-fits-all prescription.
The article, authored by a six-person team led by Fabrizio Schifano of the University of Hertfordshire and Giovanni Martinotti of G. D’Annunzio University in Chieti, is explicitly a perspective piece: it draws on the authors’ clinical experience alongside published evidence rather than reporting new trial data. That distinction matters, because the evidence base for treating depression in the presence of addiction is thin. The authors note that few evidence-based clinical guidelines exist for co-occurring depression and substance use disorder, leaving healthcare professionals to lean heavily on accumulated clinical judgment. Their stated aim is to organize that judgment into practical recommendations for the wider clinical community.
The stakes are high. Comorbid depression and substance use disorder adversely affect quality of life and neuropsychological functioning, and significantly increase the risk of disability, suicidal ideation, and mortality. Patients with the combination are also less likely to receive guideline-recommended treatment for depression than those with depression alone. In Europe, the authors report, only about 10 percent of the subset of these patients with alcohol use disorder seek drug treatment, and more than two thirds relapse within the first year of treatment. Treatment-resistant depression, which carries its own substantial clinical and psychosocial burden, may frequently coexist with alcohol or other substance use disorders, compounding the difficulty.
Diagnosis is the first bottleneck. The two disorders are bidirectional and interrelated, and the temporal relationship between them varies: substance use disorder may appear before, after, or at the same time as depression. Symptoms overlap substantially, including apathy, anhedonia, insomnia, psychomotor agitation, and emotional dysregulation, particularly with alcohol or cannabis, and substance use can exacerbate these shared symptoms. Patient-reported information may underestimate alcohol and drug misuse. The order of diagnosis often depends on where the patient first presents, with general psychiatry settings tending to code depression first and addiction settings the reverse, and depending on the substance, depression may be difficult to diagnose reliably until the patient has been detoxified. The authors call for unified screening tools, including the Beck Depression Inventory, the Patient Health Questionnaire-9, and the Major Depression Inventory, to be used consistently across all medical settings, alongside routine pretreatment screening for bipolar disorder and attention deficit hyperactivity disorder, whose presence among depressed patients is associated with more severe episodes and poorer functioning.
Who presents with which combination is itself patterned. In the authors’ experience, substance use disorder is more common among younger patients with depression, with the proportion likely exceeding 50 percent in that group. Depression with alcohol use disorder tends to present in middle-aged males alongside insomnia and anxiety, although the proportion of females is increasing, with the male-to-female ratio now approximately three to one. Young males most frequently use cannabis and novel psychoactive substances, while benzodiazepines are most frequently prescribed to females aged 50 to 64 for insomnia or anxiety, with misuse occurring more commonly in younger adults. Younger people may drink heavily without yet meeting criteria for alcohol use disorder, because that condition can take time to develop from regular use.
On treatment, the authors recommend a multifaceted approach combining non-pharmacological and pharmacotherapeutic strategies that address both conditions. Because the disorders are chronic and relapsing, patients need to be prepared for long-term therapy, and the best intervention is the one the patient will accept and adhere to. The addiction often needs to be treated first, since depression treatment may not work in the presence of ongoing substance misuse, but the required degree of detoxification varies by substance: opioid agonist therapy can take years, so depression must be treated concurrently, whereas seven to ten days can suffice to become alcohol-free and overcome withdrawal, or antidepressants can be started while alcohol intake is being reduced. For benzodiazepine dependence, withdrawal is so protracted that waiting for detoxification before starting antidepressants is not feasible.
Antidepressant selection should be individualized according to patient profile, disease characteristics, and the substance being misused. The authors highlight that selective serotonin reuptake inhibitors may show variable effectiveness in this population; a meta-analysis from 2005 found that most studies showed significant improvement of depressive scores in patients with alcohol use disorder receiving an antidepressant versus placebo, except for SSRIs, a result the authors attribute partly to heterogeneous evidence and partly to SSRIs’ limited ability to improve anhedonia and their tendency to induce emotional blunting. Anhedonia itself is a key symptom of depression that often contributes to substance use relapse. Agents with different pharmacodynamic profiles, including agomelatine, vortioxetine, and bupropion, are proposed as alternatives, and the authors note these are generally associated with favorable anti-anhedonic properties. Medications for substance use disorder, such as naltrexone for alcohol use disorder, can be combined with antidepressants to improve treatment efficacy.
A substantial portion of the article is devoted to trazodone, a serotonin antagonist and reuptake inhibitor approved for major depressive disorder with a multimodal pharmacological profile spanning serotonergic, dopaminergic, adrenergic, and histaminergic systems. Through these interactions it induces a fast antidepressant response and has sedative effects, which the authors argue makes it useful for select patients because it can also relieve the anxiety, agitation, and insomnia common in substance use disorder and potentially linked to early relapse. Trazodone has demonstrated antidepressant effectiveness in depression with alcohol use disorder and has been reported to help reduce alcohol craving, is not generally associated with addiction liability, and has a favorable safety and tolerability profile relevant to younger users who wish to avoid weight gain or sexual dysfunction. The authors also note that SARIs may be associated with less emotional blunting than SSRIs and serotonin-norepinephrine reuptake inhibitors. These are the authors’ clinical assessments, and the article’s own conclusion is that further studies specifically assessing treatments for comorbid depression and substance use disorder are required.
The article’s substance-by-substance recommendations underscore how much context shapes pharmacology. For depression with alcohol use disorder, detoxification with benzodiazepines such as diazepam or lorazepam, relapse-prevention agents such as naltrexone or acamprosate, and antidepressants with sedative properties are suggested, with awareness of seizure risk during withdrawal. For cannabis use disorder, options include gradual THC taper or supervised cessation, trazodone, mirtazapine, vortioxetine, and dopamine receptor partial agonists if psychosis is present, with motivational interviewing and family involvement flagged as particularly useful for younger patients. For benzodiazepine dependence, oxazepam substitution and tapering is proposed, and bupropion is to be avoided due to potential seizure risk during withdrawal. For cocaine or stimulant use disorder, where viable treatment options are lacking, the authors suggest brain stimulation strategies such as transcranial magnetic stimulation, dopaminergic antidepressants such as bupropion, and possibly prescription stimulants, noting that depression in these patients usually begins when substance use stops, can be long term and difficult to treat, and may require higher antidepressant dosages because receptors may have become insensitive.
Beyond the prescription pad, the authors insist that no pharmacological strategy succeeds in isolation. They recommend a team of psychiatrists, psychologists, addiction therapists, psychotherapists, and primary care physicians, supported by family members, friends, and caregivers, with engaging family in psychoeducation shown to reduce relapse risk. Cognitive behavioral therapy or other psychotherapy should be recommended to every patient for both conditions. Regular follow-up is essential, with treatment decisions re-evaluated after six months, and harm-reduction strategies may be prioritized in older patients with prolonged histories of depression, substance use, and multiple relapses. The authors also identify systemic obstacles: stigma at every level from general psychiatry to wider society, diagnostic overshadowing whereby symptoms are attributed to addiction without considering co-occurring mental illness, insufficient training of addiction psychiatrists in some countries, and oversubscribed mental health units that may refuse patients whose symptoms are attributed purely to addiction. Looking forward, they point to preliminary evidence that glucagon-like peptide 1 receptor agonists may help alleviate addictive behaviors, including a Phase II randomized trial in which the GLP-1 receptor agonist semaglutide reduced craving and some drinking outcomes in alcohol use disorder, while stressing that more evidence-based guidelines, dedicated clinical trials, integrated facilities serving both addiction and general psychiatry, and expanded addiction psychiatry training are needed before care for this underserved population improves.
Subject of Research: Clinical management of co-occurring major depressive disorder and substance use disorder
Article Title: Managing coexisting depression and substance use disorder: insights from clinical experience
Article References: Schifano, F., Martinotti, G., Wojnar, M., Homem de Melo, I., Korbel, C., & Sani, G. (2026). Managing coexisting depression and substance use disorder: insights from clinical experience. Frontiers in Psychiatry, 17, Article 1919720. https://doi.org/10.3389/fpsyt.2026.1919720
Image Credits: AI Generated
DOI: 10.3389/fpsyt.2026.1919720
Keywords: major depressive disorder, substance use disorder, comorbidity, antidepressants, trazodone, SSRIs, alcohol use disorder, detoxification, dual diagnosis, psychoeducation, harm reduction, addiction psychiatry
News Source: Glenn Wilkins. (October 29, 2026). When Depression and Addiction Collide: Experts Map a Path Through Dual Diagnosis. Scienmag.
